Citigroup
ORGS

Citigroup’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Citigroup’s Portfolio ORGS Stock Details ORGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-126
Closed -$562 – 6045
2024
Q3 		$562 Buy
+126
New +$840 ﹤0.01% 5474
2021
Q2 		– Sell
-125
Closed -$7K – 6464
2021
Q1 		$7K Sell
125
-216
-63% -$14.1K ﹤0.01% 5820
2020
Q4 		$15K Buy
341
+254
+292% +$12.2K ﹤0.01% 6806
2020
Q3 		$4K Sell
87
-145
-63% -$7.86K ﹤0.01% 7159
2020
Q2 		$14K Buy
+232
New +$14K ﹤0.01% 6875
2019
Q1 		– Sell
-50
Closed -$2K – 7852
2018
Q4 		$2K Sell
50
-80
-62% -$4.59K ﹤0.01% 7526
2018
Q3 		$7K Hold
130
– – ﹤0.01% 7445
2018
Q2 		$11K Hold
130
– – ﹤0.01% 7161
2018
Q1 		$13K Buy
+130
New +$15.4K ﹤0.01% 6947

Citigroup's ORGS Position: Q4 2024 in Review

Citigroup sold out of Orgenesis Inc. Common Stock (ORGS) in Q4 2024, closing a stake of 126 shares — an estimated $562 sold.

Citigroup first reported a position in ORGS in Q1 2018 and held it in 9 quarters. The position peaked at $15K in Q4 2020. 0 funds tracked by Wall St. Rank hold ORGS as of Q4 2024.

  • Citigroup reported no remaining Orgenesis Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
  • Citigroup sold 126 Orgenesis Inc. Common Stock shares in Q4 2024, an estimated $562.
  • Citigroup first reported a position in Orgenesis Inc. Common Stock in Q1 2018 and held it in 9 quarters.
  • Citigroup's Orgenesis Inc. Common Stock position peaked at $15K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q4 2024.

Based on Citigroup's 13F filing for Q4 2024, filed 12 Feb 2025.